Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference of 0♸5 mmol/L (SE 0♰2 with about two-thirds compliance) during a median follow-up of 4♹ years and produced a 17% proportional reduction in major atherosclerotic events (526 simvastatin plus ezetimibe vs 619 placebo rate ratio 0♸3, 95% CI 0♷4-0♹4 log-rank p=0♰021).
Richard grimm vs stem inc trial#
This trial is registered at, NCT00125593, and ISRCTN54137607.Ĥ650 patients were assigned to receive simvastatin plus ezetimibe and 4620 to placebo. The key prespecified outcome was first major atherosclerotic event (non-fatal myocardial infarction or coronary death, non-haemorrhagic stroke, or any arterial revascularisation procedure). Patients were randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo. This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247 not) with no known history of myocardial infarction or coronary revascularisation. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.
Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain.
0 kommentar(er)
